Keyphrases
Denmark
100%
National Cohort Study
75%
Multiple Sclerosis
73%
Annualized Relapse Rate
37%
Fingolimod
37%
Interferon-β (IFN-β)
37%
Emotional Demands
37%
Confidence Interval
27%
Population-based
23%
Long-term Sickness Absence
21%
COVID-19 Vaccination
18%
Infection Risk
18%
Matched Case-control Study
18%
Early childhood
18%
Clinical Disease Activity
18%
In Utero Exposure
18%
Cardiovascular Risk
18%
Sleep Disorders
18%
Relapse Pattern
18%
Natalizumab
18%
Sleep Disturbance
18%
Self-controlled Study
18%
Psoriasis Pathogenesis
18%
Disability Pension
18%
Sweden
18%
Prospective Cohort Study
18%
Registry-based
18%
Psoriasis
18%
Single-center Study
18%
MS Diagnosis
18%
Progressive MS
18%
Relapsing-remitting multiple Sclerosis
15%
Relapse Risk
15%
Disease Activity
15%
High Risk
14%
Incidence Rate
12%
Cardiovascular Disease
10%
Diagnostic Uncertainty
10%
Hazard Ratio
9%
Revaccination
9%
Vaccination
9%
Pre-vaccination
9%
Labor Market
9%
Multiple Sclerosis Treatment
8%
Individual-level Data
8%
Hypertension
7%
Adjusted Model
7%
Hospital Admission
7%
Antibiotic Prescription
7%
Multivariable
7%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
59%
Cohort Study
42%
Beta Interferon
37%
Fingolimod
37%
Disease
26%
Epileptic Absence
18%
Psoriasis
18%
Disease Activity
18%
Infection
18%
Natalizumab
18%
Cardiovascular Disease
18%
Prospective Cohort Study
18%
Recurrence Risk
15%
Antibiotics
7%
Medicine and Dentistry
Cohort Analysis
57%
Multiple Sclerosis
37%
Epileptic Absence
21%
Disease
21%
Cardiovascular Disease
18%
Disability Pension
18%
Natalizumab
18%
Fingolimod
18%
Prospective Cohort Study
18%
COVID-19 Vaccination
18%
Recurrence Risk
18%
Proportional Hazards Model
11%
Hazard Ratio
9%
Mental Disorder
5%